ClinicalTrials.gg
CompletedNCT05014828Updated Aug 24, 2025Results posted

To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid Tumors

A Phase 2 interventional study of lenvatinib and Tislelizumab in Advanced Solid Tumor, sponsored by BeiGene. Completed at 13 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-24.

Sponsored by BeiGene · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
58
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This clinical trial evaluated the safety and potential benefits of combining two cancer treatments, tislelizumab and lenvatinib, in Chinese participants with advanced or metastatic cancers, including lung, head and neck, bladder, kidney, and stomach cancer. The study included two parts: the first part assessed how safe the drug combination was, and the second part examined how well it worked.

A small group of participants initially received the drugs to determine the appropriate dose, and if the treatment was well tolerated, additional participants were treated at that dose. Participants remained on the treatment unless their cancer progressed, they experienced serious side effects, or they chose to stop.

02

Conditions studied

  • Advanced Solid Tumor

Keywords

  • Solid tumors
03

In context

Lead sponsor

BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.

Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Participants had signed an form and were able to comply with all study requirements.
  2. Participants had a and/or cytologically confirmed diagnosis of advanced solid tumors, which included one of the following types:

    • Non-Small Cell Lung Cancer (NSCLC)
    • Squamous Cell Carcinoma of the Head and Neck (SCCHN)
    • Gastric Cancer (GC)
    • Urothelial Carcinoma (UC)
    • Renal Cell Carcinoma (RCC)
  3. Participants had at least one as defined by the (RECIST), version 1.1.
  4. Tumor tissue samples (approximately 10 unstained slides) were provided for central laboratory assessment of programmed death-ligand 1 () expression in the NSCLC cohort during the screening period. These samples were also used for retrospective exploratory biomarker analyses related to treatment response and resistance across the NSCLC, SCCHN, UC, or Gastric Cancer (GC) cohorts, in a central or designated test laboratory approved by BeiGene.
  5. Participants had an (ECOG) performance of 0 or 1

Key Exclusion Criteria:

  1. For participants in the NSCLC cohort, those with active or uncontrolled, untreated were excluded. In cohorts other than NSCLC, any participant with known leptomeningeal disease or brain metastases was excluded.
  2. Participants who had received prior therapy with lenvatinib, or with antibodies targeting programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), programmed death-ligand 2 (PD-L2), or any other agents specifically targeting T-cell costimulatory or immune checkpoint pathways, were excluded.
  3. Participants with a history of interstitial lung disease, non-infectious pneumonitis, or any uncontrolled pulmonary conditions (including but not limited to pulmonary fibrosis or acute lung diseases) were excluded.
  4. Participants who were unable to swallow capsules, or who had diseases or previous procedures that significantly affected gastrointestinal function such as malabsorption syndrome, surgical resection of the stomach or small bowel, bariatric surgery, symptomatic inflammatory bowel disease, or partial/complete bowel obstruction were excluded.
  5. Participants who had experienced bleeding (classified as Grade 2 or higher according to the [CTCAE]) within 21 days prior to the first dose were excluded.

Note: Additional protocol-defined inclusion and exclusion criteria may have applied.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
58 participants (actual)

Study arms

  • Experimental
    Safety Run In

    Participants with advanced or metastatic unresectable solid tumors were enrolled to receive 400 mg of tislelizumab administered on Day 1 of each 6-week cycle, along with 20 mg of lenvatinib self-administered orally once daily, to determine the recommended Part 2 dose (RP2D).

    Drug: lenvatinib · Drug: Tislelizumab

  • Experimental
    Part 2: Squamous Cell Carcinoma of the Head and Neck (SCCHN) Cohort

    Participants with previously untreated, advanced or metastatic SCCHN received tislelizumab (400 mg administered intravenously \[IV\] every 6 weeks \[Q6W\]) in combination with lenvatinib (20 mg taken orally once daily \[QD\]) until disease progression, start of new anticancer therapy, unacceptable toxicity, withdrawal of consent, or study termination.

    Drug: lenvatinib · Drug: Tislelizumab

  • Experimental
    Part 2: Renal Cell Carcinoma (RCC) Cohort

    Systemic therapy naive participants with advanced or metastatic RCC received tislelizumab (400 mg IV Q6W) plus lenvatinib (20 mg orally QD) until disease progression, start of new anticancer therapy, unacceptable toxicity, withdrawal of consent, or study termination.

    Drug: lenvatinib · Drug: Tislelizumab

  • Experimental
    Part 2: Non-Small Cell Lung Cancer (NSCLC) Cohort

    Participants with NSCLC expressing programmed cell death-ligand 1 (PD-L1) in ≥1% of tumor cells (TC ≥1%) and who had not received prior systemic therapy received tislelizumab (400 mg IV Q6W) and lenvatinib (20 mg orally QD) until disease progression, start of new anticancer therapy, unacceptable toxicity, withdrawal of consent, or study termination; this cohort was closed early based on emerging external data.

    Drug: lenvatinib · Drug: Tislelizumab

  • Experimental
    Part 2: Gastric Cancer (GC) Cohort

    Participants with advanced GC who had received one prior line of systemic therapy were enrolled to receive tislelizumab and lenvatinib at the RP2D (tislelizumab 400 mg IV Q6W; lenvatinib 20 mg orally QD) until disease progression, start of new anticancer therapy, unacceptable toxicity, withdrawal of consent, or study termination; this cohort was closed early due to changes in the first-line standard of care.

    Drug: lenvatinib · Drug: Tislelizumab

  • Experimental
    Part 2: Urothelial Cancer (UC) Cohort

    Participants with cisplatin ineligible, systemic therapy naive advanced UC, were to be treated with tislelizumab (400 mg IV Q6W) and lenvatinib (20 mg orally QD). This cohort was closed prior to any participant enrollment based on emerging external data.

    Drug: lenvatinib · Drug: Tislelizumab

Interventions

  • Administered at the dose of 20 mg orally, once daily.

  • 400 mg administered intravenously on Day 1 of each 42-day cycle

    Also known as: BGB-A317

06

What researchers measure

Primary outcomes

  1. Safety Run-in: Number of Participants With Adverse Events (AEs)

    An adverse event refers to any unintended or unfavorable sign, symptom, or condition (including abnormal lab results) that occurs during the study, regardless of whether it is related to the study drug. A serious adverse event (SAE) is any untoward medical occurrence that, at any dose: * Resulted in death * Was life-threatening * Required hospitalization or prolongation of existing hospitalization * Resulted in disability/incapacity * Was a congenital anomaly/birth defect * Was considered a significant medical AE by the investigator based on medical judgement. A dose-limiting toxicity (DLT) was defined as a Grade 3 or 4 hematologic or nonhematologic toxicity occurring during the DLT assessment window and deemed related to one or more study drugs by the investigator.

    Time frame: From first dose through the end of the safety run-in part, up to 124 days; The DLT observation period was 28 days after first dose.

  2. Overall Response Rate (ORR)

    Overall response rate is defined as the percentage of participants who had a confirmed complete response (CR) or partial response (PR) as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 Tumor assessments. CR is defined as the disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From the first dose up to the primary analysis data cut-off date of 10 October 2023 (maximum time on study was 24.7 months)

Secondary outcomes

  1. Progression Free Survival (PFS)

    PFS was defined as the time from randomization to the first objectively documented disease progression as assessed by the investigator per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) or death from any cause, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method.

    Time frame: From the first dose up to the primary analysis data cut-off date of 10 October 2023 (maximum time on study was 24.7 months)

  2. Duration of Response (DOR)

    DOR was defined as the time from the first documented objective response to documented radiological disease progression as assessed by the investigator using RECIST v1.1, or death from any cause, whichever occurred first. Median DOR was estimated using the Kaplan-Meier method. Progressive disease is captured as at least a 20% increase in the sum of diameters of target lesions, using the smallest sum on study as the reference (including the baseline sum if it was the smallest). In addition to the 20% relative increase, the sum also had to show an absolute increase of at least 5 mm.

    Time frame: From the first dose up to the primary analysis data cut-off date of 10 October 2023 (maximum time on study was 24.7 months)

  3. Disease Control Rate (DCR)

    DCR was defined as the percentage of participants who demonstrated a confirmed complete response (CR), partial response (PR), or stable disease (SD) as the best overall response, in accordance with the RECIST version 1.1 criteria. CR was defined as the disappearance of all target and non-target lesions with no new lesions observed. Any pathological lymph nodes (whether target or non-target) were required to have a reduction in short axis to less than 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, using the baseline sum of diameters as the reference. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), using the smallest sum of diameters recorded while on study as the reference.

    Time frame: From the first dose up to the primary analysis data cut-off date of 10 October 2023 (maximum time on study was 24.7 months)

  4. Overall Survival (OS)

    OS was defined as the time from randomization to the documented date of death for participants who died on or before the data cutoff date. Median OS was calculated using the Kaplan-Meier method. Data for participants who were alive at the data cutoff date were censored at their last known alive date, defined as either the clinical cutoff date for those still on treatment or the most recent available date confirming they were alive, whichever occurred first.

    Time frame: From the first dose up to the primary analysis data cut-off date of 10 October 2023 (maximum time on study was 24.7 months)

  5. Number of Participants Experiencing Adverse Events (AEs)

    An adverse event refers to any unintended or unfavorable sign, symptom, or condition (including abnormal lab results) that occurs during the study, regardless of whether it is related to the study drug.

    Time frame: From first dose of study drug to 30 days after last dose, up to the study completion date of 10 July 2024 (up to 32.5 months)

07

Results

Posted Aug 24, 2025

Participant flow

Participants were enrolled in multiple study centers in China. The first participant dosed was on September 18th, 2021 and the last participant completed on July 10th, 2024. Enrollment began with a run-in phase to assess the safety and tolerability of tislelizumab plus lenvatinib combination therapy. Once the Safety Monitoring Committee confirmed that the combination therapy was tolerable, enrollment into the expansion phase began.

Participant flow — Overall Study
MilestoneSquamous Cell Carcinoma of the Head and Neck (SCCHN)Renal Cell Carcinoma (RCC)Non-Small Cell Lung Cancer (NSCLC)Gastric Cancer (GC)
Started272353
Treated272353
Enrolled in safety run-in stage2050
Completed0000
Not completed272353
Withdrew: Study completed by sponsor161633
Withdrew: Death11600
Withdrew: Lost to follow-up0020
Withdrew: Miscellaneous.0100

Outcome measures

PrimarySafety Run-in: Number of Participants With Adverse Events (AEs)

An adverse event refers to any unintended or unfavorable sign, symptom, or condition (including abnormal lab results) that occurs during the study, regardless of whether it is related to the study drug. A serious adverse event (SAE) is any untoward medical occurrence that, at any dose: * Resulted in death * Was life-threatening * Required hospitalization or prolongation of existing hospitalization * Resulted in disability/incapacity * Was a congenital anomaly/birth defect * Was considered a significant medical AE by the investigator based on medical judgement. A dose-limiting toxicity (DLT) was defined as a Grade 3 or 4 hematologic or nonhematologic toxicity occurring during the DLT assessment window and deemed related to one or more study drugs by the investigator.

Time frame:
From first dose through the end of the safety run-in part, up to 124 days; The DLT observation period was 28 days after first dose.
Reported as:
Count of participants · Participants
Safety Run-in: Number of Participants With Adverse Events (AEs)
ParticipantsSafety Run-In
Number of Participants with any TEAEs6
Number of Participants with any SAEs4
Number of Participants with any DLTs0
PrimaryOverall Response Rate (ORR)

Overall response rate is defined as the percentage of participants who had a confirmed complete response (CR) or partial response (PR) as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 Tumor assessments. CR is defined as the disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From the first dose up to the primary analysis data cut-off date of 10 October 2023 (maximum time on study was 24.7 months)
Reported as:
Number · Percentage of participants
Overall Response Rate (ORR)
Percentage of participantsSquamous Cell Carcinoma of the Head and Neck (SCCHN)Renal Cell Carcinoma (RCC)Non-Small Cell Lung Cancer (NSCLC)Gastric Cancer (GC)
Safety Analysis Set29.6 (13.8 to 50.2)60.9 (38.5 to 80.3)20.0 (0.5 to 71.6)33.3 (0.8 to 90.6)
Evaluable Analysis Set33.3 (15.6 to 55.3)66.7 (43.0 to 85.4)20.0 (0.5 to 71.6)33.3 (0.8 to 90.6)
SecondaryProgression Free Survival (PFS)

PFS was defined as the time from randomization to the first objectively documented disease progression as assessed by the investigator per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) or death from any cause, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method.

Time frame:
From the first dose up to the primary analysis data cut-off date of 10 October 2023 (maximum time on study was 24.7 months)
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsSquamous Cell Carcinoma of the Head and Neck (SCCHN)Renal Cell Carcinoma (RCC)Non-Small Cell Lung Cancer (NSCLC)Gastric Cancer (GC)
Progression Free Survival (PFS)6.1 (4.3 to 13.7)15.4 (8.4 to NA)6.0 (2.5 to NA)NA (1.4 to NA)
SecondaryDuration of Response (DOR)

DOR was defined as the time from the first documented objective response to documented radiological disease progression as assessed by the investigator using RECIST v1.1, or death from any cause, whichever occurred first. Median DOR was estimated using the Kaplan-Meier method. Progressive disease is captured as at least a 20% increase in the sum of diameters of target lesions, using the smallest sum on study as the reference (including the baseline sum if it was the smallest). In addition to the 20% relative increase, the sum also had to show an absolute increase of at least 5 mm.

Time frame:
From the first dose up to the primary analysis data cut-off date of 10 October 2023 (maximum time on study was 24.7 months)
Reported as:
Median · Months
Duration of Response (DOR)
MonthsSquamous Cell Carcinoma of the Head and Neck (SCCHN)Renal Cell Carcinoma (RCC)Non-Small Cell Lung Cancer (NSCLC)Gastric Cancer (GC)
Duration of Response (DOR)9.6 (2.8 to NA)NA (10.8 to NA)18.5 (NA to NA)NA (NA to NA)
SecondaryDisease Control Rate (DCR)

DCR was defined as the percentage of participants who demonstrated a confirmed complete response (CR), partial response (PR), or stable disease (SD) as the best overall response, in accordance with the RECIST version 1.1 criteria. CR was defined as the disappearance of all target and non-target lesions with no new lesions observed. Any pathological lymph nodes (whether target or non-target) were required to have a reduction in short axis to less than 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, using the baseline sum of diameters as the reference. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), using the smallest sum of diameters recorded while on study as the reference.

Time frame:
From the first dose up to the primary analysis data cut-off date of 10 October 2023 (maximum time on study was 24.7 months)
Reported as:
Number · Percentage of Participants
Disease Control Rate (DCR)
Percentage of ParticipantsSquamous Cell Carcinoma of the Head and Neck (SCCHN)Renal Cell Carcinoma (RCC)Non-Small Cell Lung Cancer (NSCLC)Gastric Cancer (GC)
Safety Analysis Set70.4 (49.8 to 86.2)87.0 (66.4 to 97.2)100.0 (47.8 to 100.0)66.7 (9.4 to 99.2)
Evaluable Analysis Set79.2 (57.8 to 92.9)95.2 (76.2 to 99.9)100.0 (47.8 to 100.0)66.7 (9.4 to 99.2)
SecondaryOverall Survival (OS)

OS was defined as the time from randomization to the documented date of death for participants who died on or before the data cutoff date. Median OS was calculated using the Kaplan-Meier method. Data for participants who were alive at the data cutoff date were censored at their last known alive date, defined as either the clinical cutoff date for those still on treatment or the most recent available date confirming they were alive, whichever occurred first.

Time frame:
From the first dose up to the primary analysis data cut-off date of 10 October 2023 (maximum time on study was 24.7 months)
Reported as:
Median · Month
Overall Survival (OS)
MonthSquamous Cell Carcinoma of the Head and Neck (SCCHN)Renal Cell Carcinoma (RCC)Non-Small Cell Lung Cancer (NSCLC)Gastric Cancer (GC)
Overall Survival (OS)NA (5.7 to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryNumber of Participants Experiencing Adverse Events (AEs)

An adverse event refers to any unintended or unfavorable sign, symptom, or condition (including abnormal lab results) that occurs during the study, regardless of whether it is related to the study drug.

Time frame:
From first dose of study drug to 30 days after last dose, up to the study completion date of 10 July 2024 (up to 32.5 months)
Reported as:
Count of participants · Participants
Number of Participants Experiencing Adverse Events (AEs)
ParticipantsSquamous Cell Carcinoma of the Head and Neck (SCCHN)Renal Cell Carcinoma (RCC)Non-Small Cell Lung Cancer (NSCLC)Gastric Cancer (GC)
Number of Participants with any TEAEs272253
Number of Participants with any SAEs171122

Adverse events

Collected over All-cause mortality data were collected from randomization through the end of the study (up to 34 months). Serious adverse events (SAEs) and treatment-emergent adverse events (TEAEs) were collected from the date of first study drug administration through 30 days after the last dose (up to 32.5 months).. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Squamous Cell Carcinoma of the Head and Neck (SCCHN)11/27 (40.7%)17/27 (63%)27/27 (100%)
Renal Cell Carcinoma (RCC)6/23 (26.1%)11/23 (47.8%)21/23 (91.3%)
Non-Small Cell Lung Cancer (NSCLC)0/5 (0%)2/5 (40%)5/5 (100%)
Gastric Cancer (GC)0/3 (0%)2/3 (66.7%)3/3 (100%)
Most frequent serious events
Showing 10 of 40
Most frequent serious events
EventSquamous Cell Carcinoma of the Head and Neck (SCCHN)Renal Cell Carcinoma (RCC)Non-Small Cell Lung Cancer (NSCLC)Gastric Cancer (GC)
MyocarditisCardiac disorders0/270/230/51/3
Alanine aminotransferase increasedInvestigations0/270/230/51/3
Aspartate aminotransferase increasedInvestigations0/270/230/51/3
HypoalbuminaemiaMetabolism and nutrition disorders0/270/231/50/3
ProteinuriaRenal and urinary disorders0/270/231/50/3
PneumoniaInfections and infestations3/270/230/50/3
Acute myocardial infarctionCardiac disorders0/272/230/50/3
DeathGeneral disorders2/270/230/50/3
COVID-19 pneumoniaInfections and infestations2/270/230/50/3
Myocardial infarctionCardiac disorders0/271/230/50/3
Most frequent other events
Showing 10 of 177
Most frequent other events
EventSquamous Cell Carcinoma of the Head and Neck (SCCHN)Renal Cell Carcinoma (RCC)Non-Small Cell Lung Cancer (NSCLC)Gastric Cancer (GC)
ProteinuriaRenal and urinary disorders7/276/235/51/3
HypertensionVascular disorders16/2715/234/51/3
HypothyroidismEndocrine disorders10/2716/233/51/3
HypokalaemiaMetabolism and nutrition disorders1/273/230/52/3
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders7/279/233/50/3
Weight decreasedInvestigations13/2713/231/50/3
COVID-19Infections and infestations4/2710/230/50/3
DiarrhoeaGastrointestinal disorders5/275/232/50/3
Upper respiratory tract infectionInfections and infestations1/270/232/50/3
Platelet count decreasedInvestigations2/278/230/50/3

Baseline characteristics

The Safety Analysis Set is defined as all participants who received ≥ 1 dose of study drug(s).

Age, Continuous
Age, Continuous(years)Squamous Cell Carcinoma of the Head and Neck (SCCHN)Renal Cell Carcinoma (RCC)Non-Small Cell Lung Cancer (NSCLC)Gastric Cancer (GC)Total
Mean61.9 ± 10.1462.3 ± 7.3865.6 ± 7.9261.3 ± 9.2962.3 ± 8.75
Sex: Female, Male
Sex: Female, Male(Participants)Squamous Cell Carcinoma of the Head and Neck (SCCHN)Renal Cell Carcinoma (RCC)Non-Small Cell Lung Cancer (NSCLC)Gastric Cancer (GC)Total
Female861015
Male19174343
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Squamous Cell Carcinoma of the Head and Neck (SCCHN)Renal Cell Carcinoma (RCC)Non-Small Cell Lung Cancer (NSCLC)Gastric Cancer (GC)Total
Chinese27235358
Other00000
08

Study locations

13 sites
  • The Second Hospital of Anhui Medical University
    Hefei, Anhui 230601, China
  • Peking University First Hospital
    Beijing, Beijing Municipality 100034, China
  • Beijing Friendship Hospital, Capital Medical University
    Beijing, Beijing Municipality 100050, China
  • Beijing Cancer Hospital
    Beijing, Beijing Municipality 100142, China
  • Beijing Luhe Hospital, Capital Medical University
    Beijing, Beijing Municipality 101149, China
  • Chongqing Cancer Hospital
    Chongqing, Chongqing Municipality 400030, China
  • The Peoples Hospital of Guangxi Zhuang Autonomous Region
    Nanning, Guangxi 530021, China
  • Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
  • Hunan Cancer Hospital
    Changsha, Hunan 410013, China
  • Jiangsu Province Cancer Hospital
    Nanjing, Jiangsu 210008, China
  • The First Affiliated Hospital of Nanchang University Branch Donghu
    Nanchang, Jiangxi 330006, China
  • Zhejiang Provincial Peoples Hospital
    Hangzhou, Zhejiang 310014, China
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310022, China
09

References and documents

Publications

  • BGB-A317-212: A Multicenter, Open-label, Phase II Study to Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Patients With Selected Solid Tumors. Poster No: 2610 presented at ASCO, Chicago, IL, May 31-June 4, 2024

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — BeiGene shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeiGene shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeiGene review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · beigene.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2021 to primary completion in Oct 2023, 25 months.

Results were first posted in Aug 2025, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2021
First posted
Aug 20, 2021
StartActual
Sep 18, 2021
Primary completionActual
Oct 20, 2023
CompletionActual
Jul 10, 2024
Results first posted
Aug 24, 2025
Last update
Aug 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05014828
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Aug 20, 2021
Start date
Sep 18, 2021
Primary completion
Oct 20, 2023
Completion
Jul 10, 2024
Results posted
Aug 24, 2025
Last update
Aug 24, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tislelizumab

Start the discussion